ES2137125A1 - La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal. - Google Patents

La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.

Info

Publication number
ES2137125A1
ES2137125A1 ES009702410A ES9702410A ES2137125A1 ES 2137125 A1 ES2137125 A1 ES 2137125A1 ES 009702410 A ES009702410 A ES 009702410A ES 9702410 A ES9702410 A ES 9702410A ES 2137125 A1 ES2137125 A1 ES 2137125A1
Authority
ES
Spain
Prior art keywords
salt
compositions
contain
glycyrrhetic acid
zinc salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009702410A
Other languages
English (en)
Other versions
ES2137125B1 (es
Inventor
Casanovas Antonio Rubiralta
Prous Santiago Rull
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vinyals S A Lab Dr
Original Assignee
Vinyals S A Lab Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vinyals S A Lab Dr filed Critical Vinyals S A Lab Dr
Priority to ES9702410A priority Critical patent/ES2137125B1/es
Publication of ES2137125A1 publication Critical patent/ES2137125A1/es
Application granted granted Critical
Publication of ES2137125B1 publication Critical patent/ES2137125B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La utilización de la sal de zinc del ácido glicirrético en preparados contra el acné y las composiciones que contienen dicha sal. Se describe la utilización de la sal de zinc del ácido glicirrético para preparar composiciones para el tratamiento tópico del acné. Se describen también composiciones de uso tópico para el tratamiento del acné que contienen como ingrediente activo la sal de zinc del ácido glicirrético,así como un procedimiento para la obtención de dicha sal.
ES9702410A 1997-11-18 1997-11-18 La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal. Expired - Fee Related ES2137125B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9702410A ES2137125B1 (es) 1997-11-18 1997-11-18 La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9702410A ES2137125B1 (es) 1997-11-18 1997-11-18 La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.

Publications (2)

Publication Number Publication Date
ES2137125A1 true ES2137125A1 (es) 1999-12-01
ES2137125B1 ES2137125B1 (es) 2000-08-16

Family

ID=8301226

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9702410A Expired - Fee Related ES2137125B1 (es) 1997-11-18 1997-11-18 La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.

Country Status (1)

Country Link
ES (1) ES2137125B1 (es)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2829937A1 (fr) * 2001-09-24 2003-03-28 Fabre Pierre Dermo Cosmetique Composition dermocosmetologique a visee anti-inflammatoire, en particulier pour le traitement de l'acne et de la dermite seborrheique
FR2829938A1 (fr) * 2001-09-24 2003-03-28 Fabre Pierre Dermo Cosmetique Composition dermocosmetologique a visee anti-inflammatoire, en particulier pour le traitement de l'acne et de la dermite seborrheique
EP1358876A1 (de) * 2002-04-30 2003-11-05 Cognis Iberia, S.L. Mikrokapseln mit Anti-Aknewirkstoffen
EP1358872A1 (de) * 2002-04-30 2003-11-05 Cognis Iberia, S.L. Verwendung von Wirkstoffmischungen mit Azelainsäure und Glycyrrhetinsäure als Anti-Aknemittel
EP1382342A1 (de) * 2002-07-18 2004-01-21 Cognis Iberia, S.L. Verwendung von Salicylsäure und Glyzyrrhetinsäure enhaltende Zusammensetzungen zur Aknebehandlung
EP1382341A1 (de) * 2002-07-18 2004-01-21 Cognis Iberia, S.L. Verwendung von Benzoylperoxid und Glyzyrrhetinsäure enthaltende Zusammensetzungen zur Aknebehandlung
WO2004009038A3 (de) * 2002-07-18 2004-05-06 Cognis Deutschland Gmbh Kosmetische zubereitungen mit antibakteriellen eigenschaften glyzyrrhetinsäure enthaltend
EP1449847A1 (de) * 2003-02-21 2004-08-25 Cognis Deutschland GmbH & Co. KG Glyzyrrhetinsäureester als Anti-Aknemittel
US7192917B2 (en) 1999-02-11 2007-03-20 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
FR2894821A1 (fr) * 2005-12-15 2007-06-22 Galderma Res & Dev Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations
US7537908B2 (en) 1999-02-11 2009-05-26 The Feinstein Institute For Medical Research Methods of diagnosing sepsis by measuring HMG1
US7632500B2 (en) 2003-09-11 2009-12-15 Cornerstone Therapeutics, Inc. Monoclonal antibodies against HMGB1
US7749959B2 (en) 2001-05-15 2010-07-06 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US8188041B2 (en) 2003-06-06 2012-05-29 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB950777A (en) * 1961-11-01 1964-02-26 Biorex Laboratories Ltd New salts of glycyrrhetinic acid
US4214000A (en) * 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
EP0552439A1 (en) * 1991-12-02 1993-07-28 VALETUDO S.r.l. Pharmaceutical preparations for topical use in the treatment of psoriasis and atopical dermatitis
WO1994002132A1 (en) * 1992-07-17 1994-02-03 Glyzinc Pharmaceuticals Limited Treatment of skin diseases
FR2710526A1 (fr) * 1993-09-29 1995-04-07 Phil International Inc Préparation cosmétique à l'oxyde de zinc et son procédé de fabrication.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB950777A (en) * 1961-11-01 1964-02-26 Biorex Laboratories Ltd New salts of glycyrrhetinic acid
US4214000A (en) * 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
EP0552439A1 (en) * 1991-12-02 1993-07-28 VALETUDO S.r.l. Pharmaceutical preparations for topical use in the treatment of psoriasis and atopical dermatitis
WO1994002132A1 (en) * 1992-07-17 1994-02-03 Glyzinc Pharmaceuticals Limited Treatment of skin diseases
FR2710526A1 (fr) * 1993-09-29 1995-04-07 Phil International Inc Préparation cosmétique à l'oxyde de zinc et son procédé de fabrication.

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192917B2 (en) 1999-02-11 2007-03-20 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US8053206B2 (en) 1999-02-11 2011-11-08 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US8138141B2 (en) 1999-02-11 2012-03-20 The Feinstein Institute For Medical Research HMG1 antibody for treating inflammatory conditions
US7537908B2 (en) 1999-02-11 2009-05-26 The Feinstein Institute For Medical Research Methods of diagnosing sepsis by measuring HMG1
US8822169B2 (en) 1999-02-11 2014-09-02 The Feinstein Institute For Medical Research HMG1 antibody for treating inflammatory conditions
US8501173B2 (en) 2001-05-15 2013-08-06 The General Hospital Corporation Antibodies to high mobility group-1(HMGB1) B-box polypeptides
US7749959B2 (en) 2001-05-15 2010-07-06 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7897569B2 (en) 2001-05-15 2011-03-01 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
FR2829937A1 (fr) * 2001-09-24 2003-03-28 Fabre Pierre Dermo Cosmetique Composition dermocosmetologique a visee anti-inflammatoire, en particulier pour le traitement de l'acne et de la dermite seborrheique
WO2003026604A1 (fr) * 2001-09-24 2003-04-03 Pierre Fabre Dermo-Cosmetique Composition dermocosmetologique a visee anti-inflammatoire, en particulier pour le traitement de l'acne et de la dermite seborrheïque
FR2829938A1 (fr) * 2001-09-24 2003-03-28 Fabre Pierre Dermo Cosmetique Composition dermocosmetologique a visee anti-inflammatoire, en particulier pour le traitement de l'acne et de la dermite seborrheique
WO2003092664A1 (de) * 2002-04-30 2003-11-13 Cognis Iberia, S.L. Mikrokapseln mit anti-aknewirkstoffen
WO2003092655A3 (de) * 2002-04-30 2004-04-15 Cognis Iberia Sl Verwendung von wirkstoffmischungen mit azelainsaure und glycyrrhetinsaure als anti-aknemittel
EP1358872A1 (de) * 2002-04-30 2003-11-05 Cognis Iberia, S.L. Verwendung von Wirkstoffmischungen mit Azelainsäure und Glycyrrhetinsäure als Anti-Aknemittel
EP1358876A1 (de) * 2002-04-30 2003-11-05 Cognis Iberia, S.L. Mikrokapseln mit Anti-Aknewirkstoffen
EP1382342A1 (de) * 2002-07-18 2004-01-21 Cognis Iberia, S.L. Verwendung von Salicylsäure und Glyzyrrhetinsäure enhaltende Zusammensetzungen zur Aknebehandlung
WO2004009038A3 (de) * 2002-07-18 2004-05-06 Cognis Deutschland Gmbh Kosmetische zubereitungen mit antibakteriellen eigenschaften glyzyrrhetinsäure enthaltend
WO2004009096A1 (de) * 2002-07-18 2004-01-29 Cognis Iberia, S.L. Verwendung von salicylsäure und glyzyrrhetinsäure enthaltende zusammensetzungen zur aknebehandlung
WO2004009095A1 (de) * 2002-07-18 2004-01-29 Cognis Ibéria, S.L. Verwendung von benzoylperoxid und glyzyrrhetinsäure enthaltende zusammensetzunden zur aknebehandlung
EP1382341A1 (de) * 2002-07-18 2004-01-21 Cognis Iberia, S.L. Verwendung von Benzoylperoxid und Glyzyrrhetinsäure enthaltende Zusammensetzungen zur Aknebehandlung
EP1449847A1 (de) * 2003-02-21 2004-08-25 Cognis Deutschland GmbH & Co. KG Glyzyrrhetinsäureester als Anti-Aknemittel
US8188041B2 (en) 2003-06-06 2012-05-29 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7632500B2 (en) 2003-09-11 2009-12-15 Cornerstone Therapeutics, Inc. Monoclonal antibodies against HMGB1
US8846047B2 (en) 2003-09-11 2014-09-30 The Feinstein Institute For Medical Research Monoclonal antibodies against HMGB1
WO2007071860A3 (fr) * 2005-12-15 2007-08-16 Galderma Res & Dev Compositions comprenant au moins un composé rétinoide et au moins un composé anti-irritant et leurs utilisations
FR2894821A1 (fr) * 2005-12-15 2007-06-22 Galderma Res & Dev Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations

Also Published As

Publication number Publication date
ES2137125B1 (es) 2000-08-16

Similar Documents

Publication Publication Date Title
DE69900081D1 (de) Haut- und/oder Haardepigmentierungsmittel
MY135988A (en) Additive for improving the water resistance of cosmetic or dermatological formulations
EP0852949A3 (en) Use of alpha-amino-acids for enhancing desmosomal degradation or stratum corneum desquamation
CA2404810A1 (en) Topical composition having undifferentiated plant seed cells and method for using same
DE69533581D1 (de) Sprühbare zubereitungen enthaltend dispernierten pulvers sowie dessen anwendungsverfahren
CA2308006A1 (en) Topical compositions for regulating the oily/shiny appearance of skin
AU3142195A (en) Dermatological compositions containing benzoyl peroxide and a compound reducing skin irritation
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
ES2137125A1 (es) La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
MXPA04000654A (es) Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
AU3956599A (en) Surfactant for use in external preparations for skin and external preparation for skin containing the same
CA2159985A1 (en) Methods of Using Hesperetin for Sebum Control and Treatment of Acne
AU3850600A (en) Dalda analogs and their use
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
CA2015838A1 (en) Method of topically treating acne vulgaris
MX9307509A (es) Metodo y preparacion farmaceutica para reducir la actividad de las celulas.
RO118174B1 (ro) Lac de unghii şi utilizarea acestuia
AU2108500A (en) Galenic formulation containing biotin
EP0209724A3 (en) Preparation effective against acne and the use of an active extract of couch grass
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
CA2207783A1 (en) Antiperspirant or deodorant composition comprising a moisturizing cream
CA2571796A1 (en) Cosmetic compositions and methods containing a tanning agent and liposome-enscapsulated ursolic acid
AU6924698A (en) Use of at least an irvingia gabonensis extract in a cosmetic and/or pharmaceutical product
CA2326528A1 (en) Cholesterol sulfate compositions for artificial skin tanning
AU3946197A (en) Cosmetic, dermatological and pharmaceutical use of a terminalia catappa extract

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991201

Kind code of ref document: A1

Effective date: 19991201

PC2A Transfer of patent
PC2A Transfer of patent
FD1A Patent lapsed

Effective date: 20071119